Literature DB >> 20385913

Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele.

Jessica B S Langbaum1, Kewei Chen, Richard J Caselli, Wendy Lee, Cole Reschke, Daniel Bandy, Gene E Alexander, Christine M Burns, Alfred W Kaszniak, Stephanie A Reeder, Jason J Corneveaux, April N Allen, Jeremy Pruzin, Matthew J Huentelman, Adam S Fleisher, Eric M Reiman.   

Abstract

OBJECTIVE: To investigate with fluorodeoxyglucose positron emission tomography whether regional reductions in the cerebral metabolic rate for glucose (CMRgl) previously found in cognitively healthy late-middle-aged apolipoprotein E (APOE) epsilon4 carriers extend to members of the Latino Mexican American community.
DESIGN: Prospective cohort study.
SETTING: Banner Alzheimer's Institute, Phoenix, Arizona. PATIENTS OR OTHER PARTICIPANTS: Eleven APOE epsilon4 carriers and 16 noncarriers from Arizona's Latino community (mean [SD] age, 54.6 [6.4] years) matched for sex, mean age, and educational level and who were predominantly of self-designated Mexican origin. MAIN OUTCOME MEASURE: A brain mapping algorithm was used to compare cross-sectional regional CMRgl in Latino APOE epsilon4 carriers vs noncarriers.
RESULTS: Participant groups had similar distributions for age, sex, education, family history of dementia, clinical ratings, and neuropsychological test scores. Latino APOE epsilon4 carriers had lower CMRgl than the noncarriers in the posterior cingulate, precuneus, and parietal regions previously found to be preferentially affected in patients with Alzheimer disease (AD) and cognitively healthy non-Latino APOE epsilon4 carriers. Additionally, the Latino APOE epsilon4 carriers had lower CMRgl in the middle and anterior cingulate cortex, hippocampus, and thalamus.
CONCLUSIONS: This study provides support for the relationship between APOE epsilon4 and risk of AD in Latino individuals. It illustrates the role of positron emission tomography as a presymptomatic endophenotype for the assessment of AD risk factors and supports the inclusion of Latino APOE epsilon4 carriers in proof-of-concept studies using fluorodeoxyglucose PET to evaluate promising presymptomatic treatments in cognitively healthy carriers of this common AD susceptibility gene.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385913      PMCID: PMC2943432          DOI: 10.1001/archneurol.2010.30

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  49 in total

1.  Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.

Authors:  Gene E Alexander; Kewei Chen; Pietro Pietrini; Stanley I Rapoport; Eric M Reiman
Journal:  Am J Psychiatry       Date:  2002-05       Impact factor: 18.112

2.  Apolipoprotein E genotyping in a sample of Colombian patients with Alzheimer's disease.

Authors:  G H Arboleda; J J Yunis; R Pardo; C M Gómez; D Hedmont; G Arango; H Arboleda
Journal:  Neurosci Lett       Date:  2001-06-08       Impact factor: 3.046

3.  A rating scale for depression.

Authors:  M HAMILTON
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-02       Impact factor: 10.154

4.  Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.

Authors:  E M Reiman; R J Caselli; K Chen; G E Alexander; D Bandy; J Frost
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

5.  Apolipoprotein E polymorphism and cognitive impairment in a bi-ethnic community-dwelling elderly sample.

Authors:  Dylan G Harwood; Warren W Barker; Raymond L Ownby; Michael Mullan; Ranjan Duara
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Jan-Mar       Impact factor: 2.703

6.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome.

Authors:  D H Silverman; G W Small; C Y Chang; C S Lu; M A Kung De Aburto; W Chen; J Czernin; S I Rapoport; P Pietrini; G E Alexander; M B Schapiro; W J Jagust; J M Hoffman; K A Welsh-Bohmer; A Alavi; C M Clark; E Salmon; M J de Leon; R Mielke; J L Cummings; A P Kowell; S S Gambhir; C K Hoh; M E Phelps
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

7.  Familial Alzheimer disease among Caribbean Hispanics: a reexamination of its association with APOE.

Authors:  Stavra N Romas; Vincent Santana; Jennifer Williamson; Alejandra Ciappa; Joseph H Lee; Haydee Z Rondon; Pedro Estevez; Rafael Lantigua; Martin Medrano; Mayobanex Torres; Yaakov Stern; Benjamin Tycko; Richard Mayeux
Journal:  Arch Neurol       Date:  2002-01

8.  Apolipoprotein-E epsilon 4 allele frequency and conferred risk for Cuban Americans with Alzheimer's disease.

Authors:  S Sevush; G Peruyera; F Crawford; M Mullan
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

9.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.

Authors:  Eric M Reiman; Kewei Chen; Gene E Alexander; Richard J Caselli; Daniel Bandy; David Osborne; Ann M Saunders; John Hardy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

10.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08
View more
  52 in total

Review 1.  Quantitative structural MRI for early detection of Alzheimer's disease.

Authors:  Linda K McEvoy; James B Brewer
Journal:  Expert Rev Neurother       Date:  2010-11       Impact factor: 4.618

Review 2.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

3.  Rhinal hypometabolism on FDG PET in healthy APO-E4 carriers: impact on memory function and metabolic networks.

Authors:  Mira Didic; Olivier Felician; Natalina Gour; Rafaelle Bernard; Christophe Pécheux; Olivier Mundler; Mathieu Ceccaldi; Eric Guedj
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

4.  Interaction of Cigarette Smoking History With APOE Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders.

Authors:  Timothy C Durazzo; Niklas Mattsson; Michael W Weiner
Journal:  Nicotine Tob Res       Date:  2015-04-06       Impact factor: 4.244

5.  Characterization of Mexican Americans with mild cognitive impairment and Alzheimer's disease.

Authors:  Sid E O'Bryant; Leigh Johnson; Valerie Balldin; Melissa Edwards; Robert Barber; Benjamin Williams; Michael Devous; Blair Cushings; Janice Knebl; James Hall
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 6.  Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases.

Authors:  S M De La Monte
Journal:  Panminerva Med       Date:  2012-09       Impact factor: 5.197

Review 7.  Imaging brain effects of APOE4 in cognitively normal individuals across the lifespan.

Authors:  Marine Fouquet; Florent L Besson; Julie Gonneaud; Renaud La Joie; Gaël Chételat
Journal:  Neuropsychol Rev       Date:  2014-08-22       Impact factor: 7.444

Review 8.  Relationships between diabetes and cognitive impairment.

Authors:  Suzanne M de la Monte
Journal:  Endocrinol Metab Clin North Am       Date:  2013-12-12       Impact factor: 4.741

Review 9.  Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease.

Authors:  Alexander Drzezga; Daniele Altomare; Cristina Festari; Javier Arbizu; Stefania Orini; Karl Herholz; Peter Nestor; Federica Agosta; Femke Bouwman; Flavio Nobili; Zuzana Walker; Giovanni Battista Frisoni; Marina Boccardi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-13       Impact factor: 9.236

10.  Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions.

Authors:  Larry G Brooks; David A Loewenstein
Journal:  Alzheimers Res Ther       Date:  2010-09-29       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.